MKI67 and neoplasm: Treatment with 3.7 MBq of 90Y-labeled NZ-16 and 18.5 kBq of 225Ac-labeled NZ-16 significantly reduced the proliferation of (Ki-67-positive) tumor cells compared with tumors treated with 0 MBq NZ-16 (intact NZ-16) on days 1–7 post injection (p < 0.01, Figure 5a,b).